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Background & Aims
The progression of chronic HCV infection varies significantly depending on patient
characteristics. The goal of the present study was to evaluate the consequences of
targeted and universal therapy for HCV-related morbidity-mortality based on the
use of non-invasive diagnostic tests in France, Italy and the UK.
Methods
A country-specific Markov model was used to predict clinical outcomes in patients
with chronic HCV mono-infection over 5 years. Therapeutic strategies used in the
three countries analysed: no treatment, targeted therapy based on stage of fibrosis
(F2- or F3-scenario), treatment regardless of stage of fibrosis (universal analysis),
base-case analysis and yearly assessments.
Results
Universal therapy is the most effective strategy and reduced the 5-year incidence
of cirrhosis by 12.0–17.7, liver complications by 4.2–5.3 and liver deaths by 3.7–4.7,
vs. no treatment. In base-case analysis, the F2-scenario using FibroScan or
patented blood biomarkers reduces the 5-year incidence of cirrhosis by 2.7–4.0,
liver complications by 3.5–3.7 and liver deaths by 3.3–3.7, vs. no treatment. The
results of the F3-scenario are poor for the incidence of cirrhosis, and moderately
effective for the liver complications. The alternative analysis with a yearly
assessment of fibrosis improves the impact of targeted therapy.
Conclusion
By quantifying the impact of different strategies of targeted therapy and universal
therapy, this study could help health agencies and experts to draft therapeutic
guidelines for HCV-related fibrosis.
Lay summary
The impact of different treatment strategies was evaluated in three countries,
France, Italy and UK, using a mathematical model. This analysis showed that: i) A
prioritization strategy of HCV treatment for patients with advanced disease would
decrease the overall impact of treatment on morbidity and mortality; and ii) A
strategy initiating HCV treatment to all would already show a benefit in reducing 5-
year morbidity and mortality.
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